.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Teva
US Department of Justice
Fuji
Merck
Cantor Fitzgerald
Argus Health
Dow
Accenture
Baxter

Generated: July 28, 2017

DrugPatentWatch Database Preview

Ranolazine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for ranolazine and what is the scope of ranolazine patent protection?

Ranolazine
is the generic ingredient in two branded drugs marketed by Gilead and Lupin Ltd, and is included in two NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ranolazine has ninety-two patent family members in twenty-nine countries.

There are fifteen drug master file entries for ranolazine. Four suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for Generic Name: ranolazine

Tradenames:2
Patents:10
Applicants:2
NDAs:2
Drug Master File Entries: see list15
Suppliers / Packagers: see list4
Bulk Api Vendors: see list78
Clinical Trials: see list78
Patent Applications: see list1,374
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:ranolazine at DailyMed

Tentative approvals for RANOLAZINE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe500MGTABLET, EXTENDED RELEASE;ORAL
► Subscribe► Subscribe1000MGTABLET, EXTENDED RELEASE;ORAL
► Subscribe► Subscribe1GMTABLET, EXTENDED RELEASE;ORAL
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXYesNo► Subscribe► Subscribe ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXYesNo► Subscribe► Subscribe ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006RXYesNo► Subscribe► SubscribeY ► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: ranolazine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-002Jan 27, 2006► Subscribe► Subscribe
Gilead
RANEXA
ranolazine
TABLET, EXTENDED RELEASE;ORAL021526-001Feb 12, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: ranolazine

Country Document Number Estimated Expiration
Australia744071► Subscribe
Russian Federation2002126615► Subscribe
Norway320986► Subscribe
World Intellectual Property Organization (WIPO)0166093► Subscribe
Portugal1096937► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RANOLAZINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2008017,C1109558Lithuania► SubscribePRODUCT NAME: RANOLAZINUM; REGISTRATION NO/DATE: EU/1/08/462/001 - EU/1/08/462/006, 0080709
C/GB08/058United Kingdom► SubscribePRODUCT NAME: RANOLAZINE OR A SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/08/462/001 - 006 20080714
2008017Lithuania► SubscribePRODUCT NAME: RANOLAZINUM; REGISTRATION NO/DATE: EU/1/08/462/001 - EU/1/08/462/006 20080709
504Luxembourg► Subscribe91504, EXPIRES: 20230709
0371Netherlands► SubscribePRODUCT NAME: RANOLAZINE OF EEN ZOUT OF SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/08/462/001-006 20080714
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Fuji
Teva
Deloitte
AstraZeneca
Healthtrust
US Department of Justice
Chubb
Cipla
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot